Zobrazeno 1 - 10
of 122
pro vyhledávání: '"Douis, Hassan"'
Autor:
Douis, Hassan
Central chondroid bone tumours are one of the most common primary bone tumours. Benign central chondroid tumours are termed enchondromas and its malignant counterpart are called chondrosarcomas. Enchondromas are frequently observed on routine imaging
Externí odkaz:
https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.742234
Autor:
Ali, Adnan, Hoyle, Alex P., Parker, Christopher C., Brawley, Christopher D., Cook, Adrian, Amos, Claire, Calvert, Joanna, Douis, Hassan, Mason, Malcolm D., Attard, Gerhardt, Parmar, Mahesh K.B., Sydes, Matthew R., James, Nicholas D., Clarke, Noel W.
Publikováno v:
In European Urology Oncology August 2020 3(4):412-419
Autor:
Andritsch, Elisabeth, Beishon, Marc, Bielack, Stefan, Bonvalot, Sylvie, Casali, Paolo, Crul, Mirjam, Delgado-Bolton, Roberto, Donati, Davide Maria, Douis, Hassan, Haas, Rick, Hogendoorn, Pancras, Kozhaeva, Olga, Lavender, Verna, Lovey, Jozsef, Negrouk, Anastassia, Pereira, Philippe, Roca, Pierre, de Lempdes, Godelieve Rochette, Saarto, Tiina, van Berck, Bert, Vassal, Gilles, Wartenberg, Markus, Yared, Wendy, Costa, Alberto, Naredi, Peter
Publikováno v:
In Critical Reviews in Oncology / Hematology February 2017 110:94-105
Autor:
Parker, Chris C., James, Nicholas D., Brawley, Christopher D., Clarke, Noel W., Ali, Adnan, Amos, Claire L., Attard, Gerhardt, Chowdhury, Simon, Cook, Adrian, Cross, William, Dearnaley, David P., Douis, Hassan, Gilbert, Duncan C., Gilson, Clare, Gillessen, Silke, Hoyle, Alex, Jones, Rob J., Langley, Ruth E., Malik, Zafar I., Mason, Malcolm D., Matheson, David, Millman, Robin, Rauchenberger, Mary, Rush, Hannah, Russell, J. Martin, Sweeney, Hannah, Bahl, Amit, Birtle, Alison, Capaldi, Lisa, Din, Omar, Ford, Daniel, Gale, Joanna, Henry, Ann, Hoskin, Peter, Kagzi, Mohammed, Lydon, Anna, O’Sullivan, Joe M., Paisey, Sangeeta A., Parikh, Omi, Pudney, Delia, Ramani, Vijay, Robson, Peter, Srihari, Narayanan Nair, Tanguay, Jacob, Parmar, Mahesh K. B., Sydes, Matthew R., for the STAMPEDE Trial Collaborative Group
Publikováno v:
STAMPEDE Trial Collaborative Group, Parker, C C, James, N D, Brawley, C D, Clarke, N W, Ali, A, Amos, C L, Attard, G, Chowdhury, S, Cook, A, Cross, W, Dearnaley, D P, Douis, H, Gilbert, D C, Gilson, C, Gillessen, S, Hoyle, A, Jones, R J, Langley, R E, Malik, Z I, Mason, M D, Matheson, D, Millman, R, Rauchenberger, M, Rush, H, Russell, J M, Sweeney, H, Bahl, A, Birtle, A, Capaldi, L, Din, O, Ford, D, Gale, J, Henry, A, Hoskin, P, Kagzi, M, Lydon, A, O'Sullivan, J M, Paisey, S A, Parikh, O, Pudney, D, Ramani, V, Robson, P, Srihari, N N, Tanguay, J, Parmar, M K B & Sydes, M R 2022, ' Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial ', PLoS Medicine, vol. 19, no. 6, e1003998 . https://doi.org/10.1371/journal.pmed.1003998
BackgroundSTAMPEDE has previously reported that radiotherapy (RT) to the prostate improved overall survival (OS) for patients with newly diagnosed prostate cancer with low metastatic burden, but not those with high-burden disease. In this final analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7eed042b139f7c5cd966c1b7b63924c
https://orca.cardiff.ac.uk/id/eprint/150285/2/pmed.1003998.pdf
https://orca.cardiff.ac.uk/id/eprint/150285/2/pmed.1003998.pdf
Autor:
Ali, Adnan, Hoyle, Alex, Haran, Áine M., Brawley, Christopher D., Cook, Adrian, Amos, Claire, Calvert, Joanna, Douis, Hassan, Mason, Malcolm D., Dearnaley, David, Attard, Gerhardt, Gillessen, Silke, Parmar, Mahesh K. B., Parker, Christopher C., Sydes, Matthew R., James, Nicholas D., Clarke, Noel W.
Importance Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::85fe820ebc2b213296c139bc8a3ff086
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hoyle, Alex P, Ali, Adnan, James, Nicholas D, Cook, Adrian, Parker, Christopher C, De Bono, Johann S, Attard, Gerhardt, Chowdhury, Simon, Cross, William R, Dearnaley, David P, Brawley, Christopher D, Gilson, Clare, Ingleby, Fiona, Gillessen, Silke, Aebersold, Daniel, Jones, Rob J, Matheson, David, Millman, Robin, Mason, Malcolm D, Ritchie, Alastair W S, Russell, Martin, Douis, Hassan, Parmar, Mahesh K B, Sydes, Matthew R, Clarke, Noel W
BACKGROUND Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::602388fa39b3dcf38e51c81173332512
Autor:
Ali, Adnan, Hoyle, Alex, James, Nicholas D, Parker, Christopher C, Brawley, Christopher D, Attard, Gerhardt, Douis, Hassan, Mason, Malcolm D, Parmar, Mahesh K B, Sydes, Matthew R., Clarke, Noel
Publikováno v:
Ali, A, Hoyle, A, James, N D, Parker, C C, Brawley, C D, Attard, G, Douis, H, Mason, M D, Parmar, M K B, Sydes, M R & Clarke, N 2019, ' 850PD-Benefit of prostate radiotherapy for patients with lymph node only or < 4 bone metastasis and no visceral metastases: Exploratory analyses of metastatic site and number in the STAMPEDE “M1|RT comparison” ', Annals of Oncology, pp. v330 . https://doi.org/10.1093/annonc/mdz248.007
Background Prostate radiotherapy (PRT) with androgen deprivation therapy (ADT) is now recommended as a first line option for de-novo low burden metastatic prostate cancer. In the STAMPEDE “M1|RT comparison” metastatic burden was a determinant of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3818::10798e6f0bdbcc073c5340707b4727ae
https://doi.org/10.1093/annonc/mdz248.007
https://doi.org/10.1093/annonc/mdz248.007